Stockreport

Zai Lab's ZL-2301 shows encouraging action in mid-stage liver cancer study [Seeking Alpha]

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF Interim data from a Phase 2 clinical trial evaluating Zai Lab's (NASDAQ: ZLAB ) ZL-2301 (brivanib) in Chinese patients with previously treated advanced hepatocel [Read more]